Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and selling targeted protein degradation medicines for cancer and inflammatory diseases. The company uses an artificial intelligence (AI)-integrated discovery engine and expertise in ligase to translate protein degradation science into clinical advancements. Nurix's wholly owned clinical pipeline includes three investigational drug candidates: bexobrutideg (NX-5948), a selective degrader of Bruton's tyrosine kinase (BTK); zelebrudomide (NX-2127), a dual degrader of BTK and transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase. The company is also developing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline includes a clinical stage degrader of IRAK4 (NX-0479/GS-6791), a preclinical stage degrader of STAT6, and multiple undisclosed targets under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. Nurix retains certain options for co-development, co-commercialization, and profit sharing in the United States for multiple drug candidates within these collaborations. Both wholly owned and partnered pipelines are powered by the DEL-AI discovery engine, which uses machine learning for DNA encoded library (DEL) hit-finding, degrader design, automated chemistry synthesis, and direct-to-biology screening and optimization to generate new chemical entity drug candidates.